Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Scientific Reports|June 17, 2022
Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trialAlex Castellarnau, Graham P Heery, Aynaz Seta, et al.
Human Vaccines & Immunotherapeutics|May 19, 2020
Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccineJohn Litt, Robert Booy, Debra Bourke, et al.
Thorax|September 28, 2019
Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trialDavid Currow, Sandra Louw, Philip McCloud, et al.
Plos One|May 5, 2020
A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosisArthur S Waldbaum, Jane R Schwebke, Jeremy R A Paull, et al.
Journal of Pain and Symptom Management|October 27, 2019
Controlled-Release Oxycodone vs. Placebo in the Treatment of Chronic Breathlessness-A Multisite Randomized Placebo Controlled TrialDiana H Ferreira, Sandra Louw, Philip McCloud, et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology: X|February 4, 2021
A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosisJane R Schwebke, Belvia A Carter, Arthur S Waldbaum, et al.
Hepatology (Baltimore, Md.)|April 2, 2009
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis BMaurizia Rossana Brunetto, Francesco Moriconi, Ferruccio Bonino, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 9, 2019
Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosisSteven E Chavoustie, Belvia A Carter, Arthur S Waldbaum, et al.
Asia-Pacific Journal of Clinical Oncology|September 30, 2017
Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancerAaron C Tan, Bob T Li, Kazi Nahar, et al.
The New England Journal of Medicine|July 1, 2005
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis BGeorge K K Lau, Teerha Piratvisuth, Kang Xian Luo, et al.
Pageof 3